Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Rounds up $15 Million in Financing

NEW YORK, Sept. 11-Screening tool and bioinformatics company Cellomics said last week that it had completed a round of financing that brought in $15 million.

 

Investors include the German optics and microscopy company Carl Zeiss, joined by Oxford Bioscience Partners, the Vector Fund, Alta Partners, and Axiom Ventures.

 

Zeiss was Cellomics' initial seed investor, and the two companies have collaborated to develop a high-throughput screening platform for lead optimization, target validation and toxicology.

 

For more information, see the press release.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.